Pneumococcal Conjugate Vaccine (PCV)
Treatment for Otitis Media
Typical Dosage: Standard vaccine schedule
Effectiveness
65%
Safety Score
85%
Clinical Trials
2
Participants
200K
Comparative Safety Scale(Higher is safer)
Cyanideā ļø
Methš
Cigarettesš¬
Chemoā¢ļø
Alcoholšŗ
Morphineš
Antibioticsš
Tylenolš
Exerciseš
Waterš§
85
DangerousModerateSafe
Treatment Details
Dosage Range
Standard vaccine schedule
Time to Effect
weeks-months (after series completion)
Treatment Duration
Childhood immunization series
Evidence Quality
HIGHNumber Needed to Treat (NNT)
25(Treat 25 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
50000(Treat 50000 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$500
Monitoring:$500
Side Effect Mgmt:$0
Total Annual:$1,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
0.2
Comparison vs No Vaccination
Cost Difference
+$500/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Pneumococcal Conjugate Vaccine (PCV) Outcomes
for Otitis Media
Efficacy Outcomes
Overall Effectiveness
+65%
Common Side Effects
Injection site reactions (pain, redness)
+40%
Fever
+10%
Irritability
+15%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
2 completed trials for Pneumococcal Conjugate Vaccine (PCV) in Otitis Media
Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea
NCT00219401COMPLETEDPHASE2
318 participants
INTERVENTIONAL
Goroka, Papua New Guinea
Started: May 1, 2005
Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life
NCT01735084COMPLETEDPHASE4
261 participants
INTERVENTIONAL
Darwin, Australia
Started: Mar 12, 2013